Richard Lowenthal is President and Chief Executive Officer of ARS Pharmaceuticals, Inc. (SPRY). The company reported total compensation of $9,656,400 for fiscal year 2025.
| Salary | $700,000 |
|---|---|
| Bonus | — |
| Stock awards | — |
| Option awards | $6,176,110 |
| Non-equity incentive plan | $315,000 |
| Pension and non-qualified deferred compensation | — |
| All other compensation | $2,465,290 |
| Total | $9,656,400 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure ARS Pharmaceuticals, Inc. filed April 29, 2026, accession 0001193125-26-191433.
| Fiscal year | Role | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | President and Chief Executive Officer | $700,000 | — | — | $6,176,110 | $315,000 | — | $2,465,290 | $9,656,400 |
| FY2024 | President and Chief Executive Officer | $700,000 | — | — | $6,176,110 | $315,000 | — | $2,465,290 | $9,656,400 |
Totals as disclosed in each year's own compensation disclosure for ARS Pharmaceuticals, Inc..
| Peer-group chief executive median | $7,089,213 |
|---|---|
| Difference from that median | $2,567,187 |
| Percentile within the disclosed peer group | 65th |
| Peers with a disclosed figure | 16 |
Medians and percentiles are computed across the peer group ARS Pharmaceuticals, Inc. discloses in its own compensation disclosure.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Richard Lowenthal this page | President and Chief Executive Officer | $9,656,400 |
| Sarina Tanimoto | Chief Medical Officer | $5,290,471 |
| Justin Chakma | Chief Business Officer | $2,888,109 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full ARS Pharmaceuticals, Inc. compensation brief.
Richard Lowenthal's compensation sits inside ARS Pharmaceuticals, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.